ABL Bio Venture Capital
South Korea, KR Β· 2 known investors
ABL Bio develops biotherapeutic drugs using dual antibody platform technology for immunotherapy cancer treatments and degenerative neurological diseases. The company is a South Korea-based biotech research firm with proprietary platforms designed to treat intractable diseases.
Also known as ABL Bio Β· μμ΄λΉμλ°μ΄μ€
Founders & leadership
Investors Β· 2
Company profile
researched Aug 2026ABL Bio is a South Korea-based biotechnology research company developing therapeutics for immuno-oncology, degenerative brain (neurodegenerative) diseases and antibody-drug conjugate (ADC) indications. Its work is organized around bispecific antibody platform technologies aimed at intractable diseases, and the company states it was the first among domestic Korean bispecific-antibody platform companies to advance candidates into clinical trials.
The pipeline is grouped into three areas. For neurodegenerative disease, the company uses a bispecific platform designed to maximize passage across the blood-brain barrier, using IGF1R as a BBB shuttle target to raise antibody delivery into the brain while improving safety and half-life. For immuno-oncology, the company develops bispecific antibodies intended to address limitations of PD-(L)1 checkpoint therapy, including minimizing the toxicity of 4-1BB-based agents and raising response rates in low-responding or resistant patients. Its ADC work targets improved therapeutic index and more stable pharmacokinetics, with an initial focus on rare blood cancers. Named programs disclosed on the company site include ABL301, ABL503, ABL111, ABL112, ABL102, ABL103, ABL104, ABL105, ABL202 (CS5001), ABL206 (NEOK001) and ABL209 (NEOK002).
Business model
ABL Bio develops proprietary drug candidates in-house and monetizes them through out-licensing and partnership agreements with pharmaceutical companies, including technology transfer agreements signed with GSK (2025-04) and Eli Lilly (2025-11), the latter accompanied by an equity investment agreement. Partner Cstone advances ABL202 (CS5001) clinically. The company is listed, publishing disclosure, share-price and financial information for investors.
Latest developments
Recent milestones disclosed by the company include US Phase 1 IND approval for ABL206 (NEOK001) in January 2025 and for ABL209 (NEOK002) in February 2025; publication of a 4-1BB review article in mAbs (2025-02), an ABL111 paper in Clinical Cancer Research (2025-07) and an ABL112 paper in JITC (2025-03); a technology transfer agreement with GSK in April 2025; technology transfer and equity investment agreements with Eli Lilly in November 2025; and recognition as a top corporate research institute by Korea's Ministry of Science and ICT in December 2025. Partner Cstone reported 100% ORR and CR for an ABL202 (CS5001) combination regimen in first-line DLBCL patients, and ABL Bio received approval for an IND amendment to evaluate an ABL503 combination regimen in a Phase 1 trial.
βΈFull profile β market position, technology, geography
Market position
The company positions itself as a leader in Korean bispecific antibody development, stating it was the first domestic bispecific-antibody platform company to enter clinical trials, and describes its aim of becoming a globally competitive novel-drug company through its platforms and pipeline.
Technology
The company's core technology is a set of bispecific (dual) antibody platforms. One platform uses IGF1R as a blood-brain-barrier shuttle target to increase antibody delivery to the brain while improving safety and half-life, underpinning its degenerative brain disease programs. A second, immuno-oncology-focused platform centers on bispecific antibodies built to reduce the toxicity associated with 4-1BB agonism and to improve response rates and overcome resistance seen with PD-(L)1 checkpoint inhibitors. A third effort develops antibody-drug conjugates engineered for greater in-vivo pharmacokinetic stability and an improved therapeutic index, aimed at rare hematologic cancers.
Geography
Headquartered in South Korea, with clinical development extending to the United States through FDA IND filings for ABL206 and ABL209.
Compiled by commissioned research from 3 cited public sources β announcements, filings, and press listed under research sources below.
Timeline Β· 8
launches, deals, and filingsThe company signed an equity investment agreement with Eli Lilly; no amount disclosed in the source.
The company reported approval of a US Phase 1 investigational new drug application for ABL209 (NEOK002).
Approval of an IND amendment to evaluate an ABL503 combination regimen in a Phase 1 clinical trial.
The company reported approval of a US Phase 1 investigational new drug application for ABL206 (NEOK001).
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 3
primary sources listed
- ABL Bio Venture Capitalablbio.com Β· web
3 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does ABL Bio Venture Capital do?
- South Korean biotech developing bispecific antibody therapeutics for cancer immunotherapy and degenerative brain diseases.
- Who founded ABL Bio Venture Capital?
- ABL Bio Venture Capital was founded by Sang Hoon Lee.
- Who are ABL Bio Venture Capital's investors?
- ABL Bio Venture Capital's investors include Atinum Investment Co. Ltd., IMM Investment Japan.
- Where is ABL Bio Venture Capital headquartered?
- ABL Bio Venture Capital is headquartered in South Korea, KR.